<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01765296</url>
  </required_header>
  <id_info>
    <org_study_id>CG100649-3-01</org_study_id>
    <nct_id>NCT01765296</nct_id>
  </id_info>
  <brief_title>Phase III Study of CG100649 in Osteoarthritis Patients</brief_title>
  <official_title>A Double-blind, Randomized, Multicenter, Active- and Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of CG100649 in Osteoarthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  6-week Efficacy Study The objective of this study is to prove the safety and&#xD;
           non-inferiority of analgesic efficacy of CG100649 2 mg vs. celecoxib 200 mg, and&#xD;
           analgesic superiority of CG100649 2 mg vs. placebo, when administered once a day in&#xD;
           patients with osteoarthritis of the hip or knee over the 6 week Treatment period. The&#xD;
           primary efficacy parameter is the difference from Baseline to Week 6 in the Western&#xD;
           Ontario and McMaster Universities Index of Osteoarthritis (WOMAC)-Pain subscale.&#xD;
&#xD;
        -  Extended Safety Study The objective of the Extended Safety Study is to collect a total&#xD;
           of 24 weeks of safety data for CG100649 including the initial 6 weeks of safety data,&#xD;
           and an additional 18 weeks of safety data for those subjects who agree on the consent&#xD;
           form to continue into the Extended Safety Study. Subjects will be administered CG100649&#xD;
           2 mg only during 18 weeks of Extended Safety Study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      1. Number of Subjects: 350 (2:2:1 ratio of experimental vs. active comparator vs. placebo&#xD;
           comparator)&#xD;
&#xD;
        2. Adverse Events will be coded to preferred term and body system using the Medical&#xD;
           Dictionary for Regulatory Activities (MedDRA)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">December 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC-Pain Subscale in the index joint</measure>
    <time_frame>6 weeks</time_frame>
    <description>The primary efficacy outcome measure will be the change in the WOMAC-Pain Subscale in the index joint at W6 (Day 42) vs. Day 1 (Visit 2, pre-dose Baseline).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>WOMAC Osteoarthritis (OA) Index</measure>
    <time_frame>Weeks 3 and 6</time_frame>
    <description>• Change in the WOMAC OA index at W3 and W6 vs. pre-dose Baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WOMAC Osteoarthritis Subscales</measure>
    <time_frame>Weeks 3 and 6</time_frame>
    <description>• Change in WOMAC OA subscales (pain, stiffness, physical function) at W3 and W6 vs. pre-dose Baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Assessment (SGA)</measure>
    <time_frame>Weeks 3 and 6</time_frame>
    <description>• Subject's Global Assessment at W3 and W6 vs. pre-dose Baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment (PGA)</measure>
    <time_frame>Weeks 3 and 6</time_frame>
    <description>• Physician's Global Assessment at W3 and W6 vs. pre-dose Baseline;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals</measure>
    <time_frame>Weeks 3 and 6</time_frame>
    <description>• Withdrawals due to lack of analgesic efficacy.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Safety Measures of Extended Safety Study</measure>
    <time_frame>24 weeks</time_frame>
    <description>Adverse events (AEs)&#xD;
Vital signs (BP, pulse rate, body temperature), 12-lead ECG&#xD;
Clinical laboratory tests (hematology, chemistry, coagulation, urinalysis), physical examination</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Localized Primary Osteoarthritis of Hip</condition>
  <condition>Localized Primary Osteoarthritis of Knee</condition>
  <arm_group>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Celecoxib 200 mg by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule by mouth, once a day for 6 weeks (Treatment Phase), followed by CG100649 2 mg, oral, for 18 weeks (Safety Phase)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CG100649 2 mg capsule by mouth, once a day for 6 weeks (Treatment Phase); CG100649 2 mg capsule by mouth, once a day for 18 weeks (Safety Phase)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG100649</intervention_name>
    <description>2 mg capsule</description>
    <arm_group_label>CG100649</arm_group_label>
    <arm_group_label>Celecoxib</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>200 mg capsule</description>
    <arm_group_label>Celecoxib</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (abbreviated)&#xD;
&#xD;
          1. Males or females, age 20 years or above, able and willing to provide written informed&#xD;
             consent&#xD;
&#xD;
          2. Knee or Hip OA diagnosed according to American College of Rheumatology guidelines&#xD;
&#xD;
          3. Chronic pain for ≥3 months from OA&#xD;
&#xD;
          4. BP [systolic 90-140 mmHg, diastolic 50-90 mmHg] and pulse rate [resting 40-100 bpm].&#xD;
&#xD;
          5. WOMAC-Pain score in the index joint must be between 4-8 on a 0-10 numerical rating&#xD;
             scale&#xD;
&#xD;
          6. Blood chemistry must be within 2x normal range&#xD;
&#xD;
          7. Urinalysis must be within normal limits; minor deviations are acceptable&#xD;
&#xD;
          8. Subjects and their sexual partners must agree to use double barrier contraception&#xD;
             during the study period and for 3 months afterward, or be at least one year post-&#xD;
             menopause, or provide proof of surgical sterility&#xD;
&#xD;
          9. For prior non-steroidal inflammatory drug (NSAID) users only, the subject has a&#xD;
             history of positive therapeutic benefit&#xD;
&#xD;
         10. Subject is willing to limit alcohol intake to 2 or less drinks per day during study&#xD;
             and the follow-up period&#xD;
&#xD;
         11. Subjects must be able to read, understand and follow study related documents.&#xD;
&#xD;
        Exclusion Criteria (abbreviated)&#xD;
&#xD;
          1. Use of any analgesics except the study medication or acetaminophen at any time&#xD;
&#xD;
          2. Use of any medications for ongoing chronic symptoms, or psychiatric disorders that&#xD;
             could significantly diminish the cognitive ability or cause behavioral changes that&#xD;
             would prevent the subject from complying with study procedures.&#xD;
&#xD;
          3. Subject is legally incompetent, or has active psychosis, or significant emotional&#xD;
             problems which are sufficient to interfere with the conduct of the study&#xD;
&#xD;
          4. Use of anticoagulants (aspirin, warfarin, heparin, etc.) within 2 weeks of V1&#xD;
&#xD;
          5. Previous history of hypersensitivity or allergy to NSAIDs, COX-2 inhibitors, carbonic&#xD;
             anhydrase inhibitors, sulfa drugs, aspirin, or acetaminophen/paracetamol&#xD;
&#xD;
          6. Subjects requiring knee or hip arthroplasty within 2 months of screening or&#xD;
             anticipating any need for a surgical procedure on the index joint during the study&#xD;
&#xD;
          7. Diagnosed or treated for active GI ulcer, GI bleeding, ulcerative colitis, or severe&#xD;
             renal, hepatic, or coagulant disorder within 6 months prior to randomization&#xD;
&#xD;
          8. History of nasal polyps, bronchospasm, urticaria, or anaphylactic shock&#xD;
&#xD;
          9. Subjects who have had surgery on the affected joint within 6 months prior to the study&#xD;
             and subjects with a prosthesis at the index joint&#xD;
&#xD;
         10. Pregnant or breast-feeding, or expecting to conceive within the projected duration of&#xD;
             the study&#xD;
&#xD;
         11. Subjects who are currently participating or have participated in other clinical&#xD;
             studies within 4 weeks of screening or in any other clinical trial evaluating NSAIDs&#xD;
             or COX-2 inhibitors within 6 months of screening&#xD;
&#xD;
         12. Subjects who have received even one dose of rofecoxib or etoricoxib at any time in&#xD;
             their life&#xD;
&#xD;
         13. History of congestive heart failure with a status of New York Heart Association II-IV,&#xD;
             ischemic heart disease, uncontrolled hypertension, peripheral arterial disease,&#xD;
             cerebrovascular disease or subjects who have one of these diseases&#xD;
&#xD;
         14. Current user of recreational or illicit drugs or has had a recent history (1 year) of&#xD;
             drug or alcohol abuse or dependence&#xD;
&#xD;
         15. History of neoplastic disease or chemotherapy within 5 years of V1, with the exception&#xD;
             of non-metastatic skin cancer that has been completely cured&#xD;
&#xD;
         16. Subjects with gout, pseudogout, inflammatory arthritis, Paget's disease of bone,&#xD;
             chronic pain syndrome, fibromyalgia, or another major joint disease&#xD;
&#xD;
         17. Subjects using i.v, i.m., or oral corticosteroids, i.a. steroids or hyaluronic acid&#xD;
             injections within 1 month of V1&#xD;
&#xD;
         18. Subjects receiving a Chinese traditional arthritis treatment within 1 week of V1&#xD;
&#xD;
         19. Subjects who are not suitable to participate in the study by the investigator's&#xD;
             clinical decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Seonggu Ro, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CrystalGenomics, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Myung Chul Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Su Jeong Yang</last_name>
    <email>sjyang@cgxinc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Seonggu Ro, PhD</last_name>
    <email>sgro@cgxinc.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hee Soo Kyung, MD, PhD</last_name>
      <phone>+82 53-200-0000</phone>
    </contact>
    <investigator>
      <last_name>Hee Soo Kyung, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>301-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Mo Kim, MD, PhD</last_name>
      <phone>+82 53-200-0000</phone>
    </contact>
    <investigator>
      <last_name>Young Mo Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHIC Ilsan Hospital</name>
      <address>
        <city>Goyang-si</city>
        <zip>410-719</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ju Hyung Yoo, MD, PhD</last_name>
      <phone>+82 31-900-0000</phone>
    </contact>
    <investigator>
      <last_name>Ju Hyung Yoo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beom Koo Lee, MD, PhD</last_name>
      <phone>+82 32-460-0000</phone>
    </contact>
    <investigator>
      <last_name>Beom Koo Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Myung Chul Lee, MD, PhD</last_name>
      <phone>+82 2 2072-0000</phone>
    </contact>
    <investigator>
      <last_name>Myung Chul Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanyang University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Choong Hyeok Choi, MD</last_name>
      <phone>82 2-2290-0000</phone>
    </contact>
    <investigator>
      <last_name>Choong Hyeok Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>135-720</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chong Hyuk Choi, MD, PhD</last_name>
      <phone>+82 10 9016-0000</phone>
    </contact>
    <investigator>
      <last_name>Chong Hyuk Choi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In Yong, MD, PhD</last_name>
      <phone>+82 2-2258-0000</phone>
    </contact>
    <investigator>
      <last_name>In Yong, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seong-Il Bin, MD, PhD</last_name>
      <phone>+82 2 3010 0000</phone>
    </contact>
    <investigator>
      <last_name>Seong-Il Bin, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boramae Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>156-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Baik Kang, MD, PhD</last_name>
      <phone>+82 2-870-0000</phone>
    </contact>
    <investigator>
      <last_name>Seung Baik Kang, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ewha Womans University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>158-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jong Oh Kim, MD, PhD</last_name>
      <phone>+82 2 2650-0000</phone>
    </contact>
    <investigator>
      <last_name>Jong Oh Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Inje University Seoul Paik Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jin Goo Kim, MD, PhD</last_name>
      <phone>+82 2-2270-0000</phone>
    </contact>
    <investigator>
      <last_name>Jin Goo Kim, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Seung Beom Han, MD, PhD</last_name>
      <phone>+82 2-920-0000</phone>
    </contact>
    <investigator>
      <last_name>Seung Beom Han, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young Wan Moon, MD, PhD</last_name>
      <phone>+82 2-3410-0000</phone>
    </contact>
    <investigator>
      <last_name>Young Wan Moon, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <study_first_submitted>January 8, 2013</study_first_submitted>
  <study_first_submitted_qc>January 9, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 10, 2013</study_first_posted>
  <last_update_submitted>April 27, 2013</last_update_submitted>
  <last_update_submitted_qc>April 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Osteoarthritis, Hip</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>July 25, 2016</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 28, 2016</submitted>
    <returned>October 19, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

